Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

BPMC 10.16.2024

Full Press ReleaseSEC FilingsOur BPMC Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.12.2025 - Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
  • 12.18.2024 - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.21.2025 - 144 Report of proposed sale of securities
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1

CAMBRIDGE, Mass.,Oct. 16, 2024/PRNewswire/ --Blueprint Medicines Corporation(NASDAQ: BPMC) today announced that it will host a live conference call and webcast at8:00 a.m. ETonWednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update.

Blueprint Medicines logo (PRNewsfoto/Blueprint Medicines Corporation)

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of theBlueprint Medicineswebsite athttp://ir.blueprintmedicines.com/. The archived webcast will be available onBlueprint Medicines'website approximately two hours after the conference call and will be available for 30 days following the call.

AboutBlueprint Medicines

Blueprint Medicinesis a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in theU.S.andEurope. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visitwww.BlueprintMedicines.comand follow us onX(formerly Twitter; @BlueprintMeds) andLinkedIn.

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2024-financial-results-on-wednesday-october-30-2024-302275822.html

SOURCEBlueprint Medicines Corporation

CONTACTS: Investor Relations Contact: Jenna Cohen, 857.209.3147, ir@blueprintmedicines.com; Media Relations Contact: Andrew Law, 617.844.8205, media@blueprintmedicines.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com